| Previous Close | 1.9600 |
| Open | 2.0000 |
| Bid | 0.0000 x 4000 |
| Ask | 0.0000 x 1100 |
| Day's Range | 1.8505 - 2.0050 |
| 52 Week Range | 1.8500 - 175.0000 |
| Volume | 415,397 |
| Avg. Volume | 422,992 |
| Market Cap | 8.394M |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -111.7070 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $14.4 million before deducting underwriting discounts and commissions and offering expenses payable by Jaguar. The Series 1 Warrants and Series 2 Warrants (together, the “warrants”) will have an exercise price of $2.00 and will be exercisable upon issuance.
SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the "Merger") from approximately $10.5 million (the "Original Debt") to approximately $4.4 million, thereby strengthening the Company's balance sheet. The Company accomplished this reduction in indebtedness through the issuance of approximately 1,119,440 shares of common stock, at a weighted average price of approximately $5.58 per share, to Chicago Venture Partners L.P. ("CVP") pursuant to exchange agreements entered into between the Company and CVP from May 29, 2019 through July 12, 2019.
SAN FRANCISCO, CA / ACCESSWIRE / July 11, 2019 / Jaguar Health, Inc. (JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that its wholly owned subsidiary, Napo Pharmaceuticals, Inc., has agreed in principal to support a U.S.-based University’s request to begin an - Institution Initiated Clinical Research Study. The University will perform a pilot study to evaluate the safety and effectiveness of crofelemer for treatment of chronic idiopathic diarrhea in non-HIV patients (the “Study”). The Study has received approval from the University’s Institutional Review Board, and Napo Pharmaceuticals, Inc. is currently negotiating the definitive agreement with the University.
SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the "Merger") from approximately $10.5 million (the "Original Debt") to approximately $5.7 million, thereby strengthening the Company's balance sheet. The Company accomplished this reduction in indebtedness through the issuance of approximately 754,838 shares of common stock, at a weighted average price of approximately $6.42 per share, to Chicago Venture Partners L.P. ("CVP") pursuant to exchange agreements entered into between the Company and CVP from May 29, 2019 through June 27, 2019.
SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has entered into a Master Services Agreement ("the Agreement") with Integrium, LLC, a clinical research organization that designs, conducts, and analyzes clinical trials. Under the terms of the Agreement and the associated service order, Intergrium will provide clinical development services to Jaguar's wholly-owned human-health subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), in support of a study to evaluate the effect of Mytesi® on the gastrointestinal microbiome in people living with HIV (PLWH).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...
SAN FRANCISCO, CA / ACCESSWIRE / June 24, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it received a letter from The Nasdaq Stock Market Inc. on June 21, 2019 confirming that the bid price deficiency of Jaguar has been cured, and that the Company is in compliance with all applicable listing standards.
SAN FRANCISCO, CA / ACCESSWIRE / June 19, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Target Animal Safety Technical Section of the Company's application for conditional approval of Canalevia™ for chemotherapy-induced diarrhea (CID) in dogs is expected to be submitted to the U.S. Food & Drug Administration's Center for Veterinary Medicine (CVM) in the third quarter of 2019. This Technical Section, which is the last of the four Technical Sections Jaguar is required to file for Canalevia for the proposed CID indication, will contain data from a 2017 target animal safety study indicating that the NOAEL (no-observed-adverse-effect level) of Canalevia in dogs is approximately six times greater than previously demonstrated, and that Canalevia is also safe for use in puppies.
SAN FRANCISCO, CA / ACCESSWIRE / June 18, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that a nonclinical pilot study to evaluate the severity of diarrhea caused by a specified dose of a specific tyrosine kinase inhibitor (TKI) in healthy dogs has been completed. A primary nonclinical study, expected to begin this July, will evaluate the effects of crofelemer on diarrhea induced in healthy dogs by the same TKI.
SAN FRANCISCO, CA / ACCESSWIRE / June 11, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that Jaguar's wholly-owned human-health subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), will receive preclinical services from the National Institute of Allergy and Infectious Diseases ("NIAID") to support the development of lechlemer, Napo's drug product candidate for a cholera indication. Under NIAID's suite of preclinical services, NIAID-funded contractors will conduct toxicology testing for 7-day rat and dog studies.
SAN FRANCISCO, CA / ACCESSWIRE / June 6, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-70 (the "Reverse Stock Split"), on Friday, June 7, 2019 (the "Effective Date"). The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on the Nasdaq Capital Market under the symbol "JAGX".
SAN FRANCISCO, CA / ACCESSWIRE / June 5, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that Lisa Conte, Jaguar's president and chief executive officer, James Bochnowski, chairman of the Company's board of directors, and Jonathan Siegel, a member of the Company's board of directors, have participated in the Company's bridge financing transaction by entering into securities purchase agreements as part of the offering described below. On March 18, 2019, Jaguar began entering into securities purchase agreements (each, a "Securities Purchase Agreement") with selected accredited investors (each, an "Investor"), pursuant to which the Company may issue up to $5.5 million aggregate principal amount of promissory notes (collectively, the "Notes") to such Investors.
SAN FRANCISCO, CA / ACCESSWIRE / June 3, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has received a one-year extension on approximately $10.5 million aggregate amount of secured debt that was previously scheduled to mature on December 31, 2019 (the "Existing Debt"). The Existing Debt was incurred in conjunction with the merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. ("Napo"). Following the merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for Mytesi (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
SAN FRANCISCO, CA / ACCESSWIRE / May 29, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to Chicago Venture Partners L.P. ("CVP") in July 2017 through March 2018. The Company accomplished this reduction in indebtedness through the issuance of approximately 27,717,914 shares of common stock, at an average price of approximately $0.23 per share, to CVP pursuant to exchange agreements entered into between the Company and CVP from January through May 2019.
All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / May 24,2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing ...
SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today reported first quarter 2019 results and issued the following highlights.
SAN FRANCISCO, CA / ACCESSWIRE / April 25, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably ...
SAN FRANCISCO, CA / ACCESSWIRE / April 10, 2019 / Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today reported fourth quarter 2018 results and issued the following highlights. Total Mytesi prescription volume, which is the combination of new prescriptions and refills, as reported by IQVIA, grew 20% in the fourth quarter of 2018 versus the prior quarter, and increased 94% over the fourth quarter of 2017.
SAN FRANSISCO, CA / ACCESSWIRE / April 2, 2019 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, issued the following updates today regarding the Company's March 28, 2019 meeting with the U.S. Food & Drug Administration (FDA) to review the protocol for Napo's planned Phase 3 clinical trial in cancer subjects to evaluate the effects of Mytesi® (crofelemer) in prevention and/or relief of cancer therapy-related diarrhea (CTD). Participants in the meeting, which was with the FDA's Division of Gastroenterology and Inborn Errors Products, included Pravin Chaturvedi, Ph.D., Napo's/Jaguar's Chairman of the Scientific Advisory Board (SAB) and Acting Chief Scientific Officer, regulatory affairs, medical safety monitoring, and biostatistics specialists, and academic key opinion leaders (KOLs)/SAB members from leading oncology treatment institutions, one of whom will serve as the Principal Investigator (PI) for the Company's planned trial.
NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Jaguar Health, Inc. (JAGX), is a commercial stage natural-products pharmaceuticals company that focuses on developing gastrointestinal products for human prescription use and animals worldwide. Mytesi® (crofelemer), is a product of Jaguar's wholly-owned subsidiary Napo Pharmaceuticals, is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, ...
CORAL GABLES, FL/ ACCESSWIRE / March 27, 2019 / The future of the biotech stock is predicated on the belief that the biotech sector is aptly prepared to develop innovative treatment options for patients in need. Through the use of machine learning, data analytics, genome sequencing, and other biotechnological advancements, companies in the biotech sector are working hard to improve the quality of life for consumers. Premier Health Group (PHGRF) (PHGI), Amyris Inc (AMRS), Jaguar Health Inc (JAGX), and AVEO Pharmaceuticals Inc (AVEO) are 4 healthcare companies making biotech companies making moves on Wednesday.
SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2019 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has completed the filing with the U.S. Food & Drug Administration's Center for Veterinary Medicine (CVM) of the Chemistry, Manufacturing, and Controls (CMC) Technical Section in support of the Company's application for conditional approval of Canalevia™ (crofelemer delayed-release tablets) for treatment of chemotherapy-induced diarrhea (CID) in dogs. Canalevia™, Jaguar's lead veterinary drug product candidate, is a canine-specific oral formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree, which is sustainably harvested.
Whereas other sectors may cut corners or decrease quality in the name of revenue, healthcare companies do not have this luxury. As consumers, we expect the healthcare industry to create products and treatments to help us feel better and to invest in future technologies so that medical professionals can assist their patients in preventive medicine, not just reactive care. The healthcare industry has demonstrated in the first few months of 2019 that these expectations are more than fair, and if companies in the sector continue to prove their aptitude for helping patients, this may catalyze investor interest in the future.
All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / March 5, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing ...